Malignant Intracranal High Grade Glioma and Current Treatment Strategy
Malignant Intracranal High Grade Glioma and Current Treatment Strategy
复制标题
恶性颅内高级别胶质瘤和当前的治疗策略。
DOI：
10.2174/1568009618666180530090922
复制
发表时间：
2019
影响因子：
3
通讯作者：
Hu Shi Jie
中科院分区：
文献类型：
--
作者：
Zhang Xiang;Zhang Wei;Mao Xing Gang;Cao Wei Dong;Zhen Hai Ning;Hu Shi Jie
恶性高级别胶质瘤（HGG）是最常见和极致命的原发性颅内肿瘤。这些肿瘤在大多数情况下在肿瘤切除的原发区域的2至3cm内复发。此外，血脑屏障显著限制了许多全身给药的化疗药物进入肿瘤，这表明迫切需要新的治疗模式。因此，使用局部药物递送的HGG靶向治疗成为开发新的治疗策略的优先事项。HGG有效化疗的主要目标包括将药物递送至肿瘤区域和将化疗药物直接输注至肿瘤的血管供应，这可以通过增强药物递送至肿瘤组织来改善药代动力学特征。本文综述了HGG的临床和分子特征、不同的化疗方法，特别是局部给药靶向治疗HGG的研究进展，可有效抑制HGG的侵袭、增殖和复发，从而对抗HGG的致命疾病。因此，以HGG为靶点的新型化学药物的开发无疑是神经肿瘤学研究的重要方向之一。
Malignant high-grade glioma (HGG) is the most common and extremely fatal type of primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for HGG becomes a priority for the development of novel therapeutic strategies. The main objectives to the effective use of chemotherapy for HGG include the drug delivery to the tumor region and the infusion of chemotherapeutic agents into the vascular supply of a tumor directly, which could improve the pharmacokinetic profile by enhancing drug delivery to the neoplasm tissue. Herein, we reviewed clinical and molecular features, different methods of chemotherapy application in HGGs, especially the existing and promising targeting therapies using local drug delivery for HGG which could effectively inhibit tumor invasion, proliferation and recurrence of HGG to combat the deadly disease. Undoubtedly, novel chemical medicines targeting these HGG may represent one of the most important directions in the Neuro-oncology.